title: PUVA treatment of the nasal cavity improves the clinical symptoms of allergic rhinitis and inhibits the immediate-type hypersensitivity reaction in the skin.
abstract: We earlier reported that intranasal irradiation with the 308 nm xenon chloride (XeCl) ultraviolet-B laser and irradiation with a combination of ultraviolet-B (UVB), ultraviolet-A (UVA) and visible light (VIS) is highly effective in the treatment of allergic rhinitis and inhibit the immediate-type hypersensitivity reaction in the skin. Since photochemotherapy with 8-methoxypsoralen (8-MOP) plus UVA light (PUVA) is widely used in the treatment of different inflammatory skin disorders due to its immunosuppressive effect, in the present study we investigated the efficacy of intranasal PUVA treatment in allergic rhinitis and the effect of PUVA treatment on the skin prick test (SPT) reaction. An open study was performed in 17 patients with hay fever. Intranasal PUVA therapy was given four times weekly for 3 weeks. The treatment was started with a fluence of 0.5x of the individual minimal phototoxic dose (MPD) and the dosages were gradually increased. Evaluation was based on the symptom scores. The effect of PUVA treatment on the allergen-induced wheal formation was also studied in the SPT. PUVA treatment of the nasal cavity significantly decreased the nasal symptoms of the patients with allergic rhinitis. Treatment of the skin with PUVA also significantly suppressed the allergen-induced wheal formation in the SPT reaction. These data suggest that intranasal PUVA phototherapy is also an effective modality in the treatment of allergic rhinitis.
authors.affiliation: Department of Dermatology and Allergology, University of Szeged, P.O. Box 427, H-6701 Szeged, Hungary.
authors.forename: Zsanett
authors.initials: Z
authors.lastname: Csoma
authors.forename: Andrea
authors.initials: A
authors.lastname: Koreck
authors.forename: Ferenc
authors.initials: F
authors.lastname: Ignacz
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Bor
authors.forename: Gabor
authors.initials: G
authors.lastname: Szabo
authors.forename: Laszlo
authors.initials: L
authors.lastname: Bodai
authors.forename: Attila
authors.initials: A
authors.lastname: Dobozy
authors.forename: Lajos
authors.initials: L
authors.lastname: Kemeny
mesh_terms: D000281:Administration, Intranasal; D000328:Adult; D031164:Ambrosia; D005260:Female; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000517:prevention & control*; D008297:Male; D008730:Methoxsalen / Q000008:administration & dosage / Q000627:therapeutic use*; D009296:Nasal Cavity / Q000187:drug effects* / Q000528:radiation effects; D011701:PUVA Therapy; D018579:Patient Selection; D010778:Photochemotherapy / Q000379:methods; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy* / Q000276:immunology; D012867:Skin / Q000276:immunology*
chemical_list: D008730:Methoxsalen